Radius rises on Phase I breast cancer readout
Radius Health Inc. (NASDAQ:RDUS) gained $4.19 (15%) to $31.60 after reporting data from the Phase I 005 trial of elacestrant (RAD1901) in heavily pretreated, estrogen receptor-positive, HER2-negative patients with advanced breast cancer. Early next year, the company plans to start a “potentially pivotal” Phase II trial in estrogen receptor-positive, HER2-negative patients with advanced or metastatic breast cancer.
Among 22 evaluable postmenopausal patients treated in the trial’s first three parts, once-daily 400 mg oral elacestrant led to an objective response rate (ORR) of 27.3%. There were six confirmed partial responses and eight cases of stable disease. Median progression-free survival (PFS) and median duration of response were 5.4 months and 17.4 weeks, respectively...